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Abstract
Objectives—The neuropeptide Y2 G-protein-coupled receptor (NPY2R) relays signals from
PYY or neuropeptide Y toward satiety and control of body mass. Targeted ablation of the NPY2R
locus in mice yields obesity, and studies of NPY2R promoter genetic variation in more than 10
000 human participants indicate its involvement in control of obesity and BMI. Here we searched
for genetic variation across the human NPY2R locus and probed its functional effects, especially
in the proximal promoter.
Methods and results—Twin pair studies indicated substantial heritability for multiple
cardiometabolic traits, including BMI, SBP, DBP, and PYY, an endogenous agonist at NPY2R.
Systematic polymorphism discovery by resequencing across NPY2R uncovered 21 genetic
variants, 10 of which were common [minor allele frequency (MAF) >5%], creating one to two
linkage disequilibrium blocks in multiple biogeographic ancestries. In vivo, NPY2R haplotypes
were associated with both BMI (P =3.75E–04) and PYY (P =4.01E–06). Computational
approaches revealed that proximal promoter variants G-1606A, C-599T, and A-224G disrupt
predicted IRF1 (A>G), FOXI1 (T>C), and SNAI1 (A>G) response elements. In neuroendocrine
cells transfected with NPY2R promoter/luciferase reporter plasmids, all three variants and their
resulting haplotypes influenced transcription (G-1606A, P <2.97E–06; C-599T, P <1.17E–06;
A-224G, P <2.04E–06), and transcription was differentially augmented or impaired by
coexpression of either the cognate full-length transcription factors or their specific siRNAs at each
site. Endogenous expression of transcripts for NPY2R, IRF1, and SNAI1 was documented in
neuroendocrine cells, and the NPY2R mRNA was differentially expressed in two neuroendocrine
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tissues (adrenal gland, brainstem) of a rodent model of hypertension and the metabolic syndrome,
the spontaneously hypertensive rat.
Conclusion—We conclude that common genetic variation in the proximal NPY2R promoter
influences transcription factor binding so as to alter gene expression in neuroendocrine cells, and
consequently cardiometabolic traits in humans. These results unveil a novel control point,
whereby cis-acting genetic variation contributes to control of complex cardiometabolic traits, and
point to new transcriptional strategies for intervention into neuropeptide actions and their
cardiometabolic consequences.
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INTRODUCTION
The neuropeptide Y (NPY) receptor Y2 (NPY2R; OMIM 162642; IUPHAR Y2) is a G-
protein-coupled receptor responding to hormones peptide YY (PYY) [1] and NPY to control
appetite and cardiovascular homeostasis. There are five subtypes of NPY receptor identified
in mammals, four of which are functional in humans. Sub-types Y1 and Y5 have known
roles in the stimulation of feeding, whereas Y2 and Y4 seem to have roles in appetite
inhibition. NPY2R is widely expressed in tissues pertinent to cardiometabolic control,
including the arcuate nucleus, a major integrator of appetite control in the hypothalamus. In
previous studies, NPY2R genetic variants were associated with obesity or BMI in several
populations, including whites [2,3], Asians [4], and Africans [5]. Indeed, studies of NPY2R
promoter genetic variation in more than 10 000 individuals [2,3,6] indicate its involvement
in control of obesity or BMI (on-line Table 1, http://links.lww.com/HJH/A209). NPY2R
also cooperates with NPY in stress-induced obesity and the metabolic syndrome [7]. NPY2R
genetic variants associate with such human cardiometabolic traits as high-density lipoprotein
cholesterol [8], SBP [3], type 2 diabetes in men [9], and left ventricular hypertrophy [10].
Hypothalamus-targeted NPY2R-knockout mice showed a decrease in body weight despite
an increase in food intake [11]. In the rat (http://rgd.mcw.edu), the Npy2r genetic locus
underlies the confidence interval of a quantitative trait locus (QTL) for blood pressure (BP):
BP QTL-90 (Bp90) [12]. Such diverse evidence indicates that NPY2R plays an
indispensable role in the cardiometabolic syndrome.
In these studies, we first documented the role of heredity in cardiometabolic traits, using
twin pair variance components, and then systematically searched for naturally occurring
genetic variation across the human NPY2R locus. Because several of the discovered
common variants occurred in a likely functional domain (the promoter), we probed their
mechanistic consequences, beginning with bioinformatic motif analysis and proceeding to
transfected promoter/luciferase reporter plasmids, site-directed mutagenesis, and
characterization of trans-acting factors. We developed evidence that variation in the NPY2R
promoter, especially at common variants G-1606A, C-599T, and A-224G, disrupt particular
motifs (IRF1, FOXI1, and SNAI1 elements, respectively), creating differential cis-
interactions and trans-interactions, to alter transcriptional activity and ultimately BP, body
mass, and associated risk traits in the population.
PARTICIPANTS AND METHODS
Genomics
Systematic polymorphism discovery at the NPY2R locus—We studied the
NPY2R locus in n =80 participants (2n =160 chromosomes) as described below under
‘Human participants’. Genomic DNA was prepared from leukocytes as described previously
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[13]. Public draft human genome sequences were obtained from the University of
California, Santa Cruz Genome Bioinformatics website (http://genome.ucsc.edu) and used
as a scaffold for primer design. The base position numbers were according to the National
Center for Biotechnology Information (NCBI) NPY2R source clone, RefSeq gene/transcript
NM_000910.2. Promoter positions were numbered upstream of (−) the NPY2R exon-1 start
(cap) site. PCR primers were designed by primer-3 [14] (http://frodo.wi.mit.edu/primer3/) to
capture approximately 2000 bp of the proximal promoter, between approximately 500 bp to
approximately2000 bp over each of the two exons (including 5′-UTR, 3′-UTR, and exon/
intron borders), and regions highly conserved across species. Target regions were amplified
and then dideoxy-sequenced using an ABI-3100 capillary sequencer (Applied Biosystems,
Carlsbad, California, USA). Polymorphism (typically as heterozygosity) was visualized on
the Applied Biosystems (ABI) tracings using Codon Code Aligner (http://
www.codoncode.com/aligner).
Human participants
Resequencing the NPY2R locus—Human studies were approved by the University of
California, San Diego (UCSD) Human Research Protection Program. Experiments were
conducted with the understanding and consent of each participant. We studied the NPY2R
locus in n =80 participants (2n =160 chromosomes) from four diverse biogeographic
ancestry groups systematically sequenced for polymorphism discovery across the NPY2R
locus: white (European ancestry, 2n =46 chromosomes), black (sub-Saharan African
ancestry, 2n =50 chromosomes), Hispanic (Mexican American, 2n =32 chromosomes), and
east Asian (2n =32 chromosomes).
UCSD twin pairs—Twin recruitment included access to a population birth record-based
twin registry [15], as well as by newspaper advertisement, as described [16]. Description of
the 362 participants in the twin heritability and allelic association studies has been published
[17]. For human allelic and haplotype association studies, this twin group was expanded to
693 participants of European ancestry, derived from additional siblings from twinships and
sibships, as previously described [18].
Statistics and informatics
Linkage disequilibrium and haplotypes—In the resequenced participants, patterns of
linkage disequilibrium as well as haplotype frequencies were analyzed and visualized by the
software Haploview (Broad Institute, Massachusetts, USA) [19]. Linkage disequilibrium
blocks were derived by the confidence interval criterion and visualized by r2 plot in
Haploview from unphased diploid genotypes of n =80 resequenced participants (2n =160
chromosomes) from four diverse biogeographic ancestry groups systematically sequenced
across the NPY2R locus. Common variants (minor allele frequency >5%) were used to
establish linkage disequilibrium.
In the twins and siblings, haplotype-on-trait analyses were conducted by regression in R
(reporting effect size as β, or slope per allele, as well as its SEM) with Haplo.glm in
Haplo.stats [20] (http://mayoresearch.mayo.edu/schai-d_lab/software.cfm). Trait-associated
haplotype GTT was present on 11.1 of chromosomes analyzed.
Bioinformatics: computational prediction of transcription factor-binding
motifs overlying NPY2R promoter common variants—Multiple sequence
alignments were performed by Clustal-W [21] (http://www.ebi.ac.uk/Tools/clustalw2/).
Potential transcription factor binding motifs were predicted from the JASPAR [22] (http://
jaspar.genereg.net/) and ConSite [23] (http://asp.ii.uib.no:8090/cgi-bin/CONSITE/consite/)
databases.
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Heritability and pleiotropy (shared genetic determination or genetic
covariance, (ρG)—Estimates of heritability (h2) (h2 =VG/VP, wherein VG is additive
genetic variance and VP is total phenotypic variance) were obtained using the twin-pair
variance-component methodology implemented in the Sequential Oligogenic Linkage
Analysis Routines (SOLAR) package [24] available at (http://txbiomed.org/departments/
genetics/). This method maximizes the likelihood assuming a multivariate normal
distribution of phenotypes in twin pairs (monozygotic versus dizygotic) with a mean
dependent on a particular set of explanatory covariates. The null hypothesis (H0) of no
heritability is tested by comparing the full model, which assumes genetic variation (VG), and
a reduced model, which assumes no genetic variation, using a likelihood ratio test.
Heritability estimates were adjusted for age and sex because of the effects of these
covariates on several traits. Pleiotropy (genetic covariance for two correlated, heritable
traits; i.e., the cross-product of trait heritabilities) [25] was estimated as the parameter ρG in
SOLAR [25]. SOLAR also estimated the environmental covariance, as parameter ρE.
Functional studies of NPY2R genetic variation
Human phenotyping: peptide YY—Human PYY (total) was measured using a Linco
(Millipore, St. Charles, Missouri, USA) HRP-TMB ELISA kit (catalog # EZHPYYT66K).
EDTA-anticoagulated plasma was frozen and stored at −70°C prior to assay; this ELISA
measures the enzyme by absorbance at 450 nm. The assay sensitivity is 1.4 pg/ml plasma,
with an intra-assay coefficient of variability (CV) of 0.9–5.8%, and interassay CV of 3.7–
16.5%. The assay equivalently recognizes PYY1–36 and PYY3–36, but does not cross-react
(at up to 50 nmol/l) with NPY, ghrelin, gastric inhibitory polypeptide, glucagon, glucagon-
like peptide-1, leptin, insulin, C-peptide, amylin, or adiponectin. PYY distribution in human
individuals was tested by the one-sample, two-tailed nonparametric Kolmogorov–Smirnov
test in SPSS (IBM Corporation, New York, USA); untransformed PYY deviated from
normality (P =0.002), whereas log[10]-transformed PYY did not display such deviation (P
=0.291). Estimates of heritability (by variance components in SOLAR; see above) did not
differ when performed on untransformed versus log[10]-transformed PYY data (see
RESULTS).
Human single nucleotide polymorphism genotyping and marker-on-trait
association—Single nucleotide polymorphism (SNP) genotypes at rs6851222 (Promoter
G-1606A), rs6857715 (Promoter C-599T), and rs1047214 (Exon-2 T/C Ile195Ile) were
chosen to span the NPY2R locus, and typed by the TaqMan method on an ABI-7900HT Fast
Real-Time PCR System, with labeled probes synthesized at Applied Biosystems. Each SNP
was in Hardy Weinberg equilibrium (all P >0.05). Haplotypes were derived from diploid
genotype data, and haplotype-on-trait analyses were conducted by regression [20], or by
Generalized Estimating Equations, with analyses adjusted for age, sex, and biogeographic
ancestry.
NPY2R promoter haplotype/luciferase reporter design and construction—
Human NPY2R promoter fragments, corresponding to NPY2R-2323/+130 bp in NPY2R
(NCBI NPY2R source clones: RefSeq gene/transcript NM_000910.2), were PCR-amplified
from genomic DNA (after resequencing) and cloned into the polylinker (between KpnI and
BglII sites) of the promoterless firefly luciferase reporter plasmid pGL3-Basic (Promega,
Madison, Wisconsin, USA), as described [13]. Site-directed mutagenesis (QuikChange;
Stratagene, Santa Clara, California, USA) created the required variant at position −1606,
−599, and −224 (Supplemental Digital Content Fig. S1, http://links.lww.com/HJH/A209).
Super-coiled plasmids were purified using NucleoBond Xtra Maxi kits (740414.10;
Machery-Nagel, Bethlehem, Pennsylvania, USA) prior to transfection, and verified by
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sequencing. Promoter positions are numbered upstream (−) of the transcriptional start (cap)
site.
Luciferase reporter assays of NPY2R promoter variants—PC12 rat
pheochromocytoma cells were transfected (at 60–80% confluence, 1 day after 1 : 4 splitting
in 24-well plate) with 500 ng of supercoiled promoter/firefly luciferase reporter plasmid per
well, by the liposome method (Transfectin; Bio-Rad, Hercules, California, USA). The firefly
luciferase activity in cell lysates was measured 24 h after transfection, using the luciferase
assay system (Promega), and the results were expressed as the ratio of firefly activity/total
protein in the lysate, as described [13]. Each experiment included at least three replicates.
Results were expressed as mean ± SEM. Statistical significance was calculated using
Student’s t-test or ANOVA, and significance was established at the P value less than 0.05
level. Inspection of the NCBI Gene Expression Omnibus (GEO) database (http://
www.ncbi.nlm.nih.gov/geo/) indicates that transcripts for NPY2R are abundantly expressed
in the adrenal gland (GEO dataset GDS3556 and GDS2374) as well as PC12 chromaffin
cells (GDS2555).
Exogenous/cotransfected transcription factors—Eukaryotic expression plasmids
containing cDNAs encoding transcription factors IRF1 (rat; clone ID 7099391), FOXI1
(human; clone ID 5185923) and SNAI1 (human; clone ID 4537122) were from Open
Biosystems (Huntsville, Alabama, USA). cDNAs were obtained in either pExpress-1 or
cytomegalovirus promoter (pCMV)-SPORT6 plasmids, and subcloned if needed into a
eukaryotic pCMV expression vector (pcDNA-3.1). One hundred nanograms of each
transcription factor expression plasmid, or 100 ng pcDNA-3.1 empty vector (control), was
cotransfected into PC12 cells, along with 500 ng of NPY2R promoter/luciferase reporter,
wild-type versus variants. After 24 h, cells were lysed and luciferase activities were assayed
as described above and normalized by total protein. Response of the NPY2R promoter to
exogenous transcription factor was revealed by comparison of the normalized luciferase
activity between the transcription factor-transfected group and the mock-transfected (empty
vector, pcDNA 3.1) group.
Exogenous/cotransfected siRNAs—Silencer select predesigned siRNAs targeting
IRF1 (rat; siRNA ID s127967), FOXI1 (rat; siRNA ID s220491), or SNAI1 (rat; siRNA ID
s137986) were from Ambion (Applied Biosystems). Silencer select negative control #1
siRNA (part number 4390843) was used as the negative control. Six nanomoles per litre
final concentration of each transcription factor siRNA, or negative control siRNA, was
cotransfected into PC12 cells, along with 500 ng of NPY2R promoter/luciferase reporter
wild-type versus variant. After 24 h, cells were lysed and luciferase activities were assayed
as described above and normalized by total protein. Response of the NPY2R promoter to
exogenous siRNAs was revealed by comparison of the normalized luciferase activity
between the transcription factor siRNA-transfected group and the mock-transfected
(negative control siRNA) group.
Quantification of endogenous transcripts by real-time PCR: NPY2R itself and
transcripts for factors whose binding motifs are disrupted by NPY2R
promoter variants (IRF1, FOXI1, SNAI1)—Total RNA was extracted from cells
(neuroendocrine PC12) or organs under each experimental state, using an ABI 6700
automated nucleic acid workstation, and quantitative real-time PCR (RT-PCR) was
performed on mRNA→cDNA with the ABI-7700 TaqMan platform, using fluorescent
reporter-tagged oligonucleotide primers, and normalization of data to β-actin expression in
the same sample. Threshold cycle (Ct) is determined for both the specific target mRNA/
cDNA as well as β-actin, and the difference in Ct (for target mRNA versus β-actin mRNA)
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is normalized to the average for that state (e.g., control versus experimental), by the ΔΔCt
method [26].
Experimental animals: spontaneously hypertensive rat and Wistar–Kyoto rat
—Animal studies were performed with age-matched, adult (12–17 weeks) male
spontaneously hypertensive rat (SHR) and Wistar–Kyoto (WKY) rat strains from Charles
River Laboratories (Wilmington, Massachusetts, USA). Features of the Charles River
colonies, including BP monitoring, are given at (http://www.criver.com/EN-US/
PRODSERV/BYTYPE/RESMODOVER/RESMOD/Pages/SHRRat.aspx). Isoflurane was
used for terminal anesthesia of SHR and WKY rats. Adrenal glands and brainstem were
isolated from each rat (n =9 per group), immediately frozen in liquid nitrogen, and then
stored at −80°C prior to RNA extraction and RT-PCR. Rats were studied according to a
protocol approved by the Animal Subjects Committee of the University of California at San
Diego, and research was conducted in accordance with institutional guidelines.
RESULTS
Heredity, pleiotropy, and cardiometabolic traits in humans
Twin pair variance component analyses indicate that multiple cardiometabolic traits display
substantial and significant (P =0.0001) heritability (h2) (Fig. 1a), including BMI (h2 =86 ±
2%), SBP (h2 =46 ± 6%), DBP (h2 =52 ± 6%), and circulating PYY (h2 =51 ± 6%), the
principal endogenous ligand for the NPY2R. Heritability estimates for BMI, SBP, and DBP
were consistent with previously reported values [17]. Using the twin method, we also
investigated genetic pleiotropy (shared genetic determination or genetic covariance) between
BMI and other cardiometabolic traits (Fig. 1b). BMI displayed significant genetic
covariance with SBP (P =9.31E–05), DBP (P =7.74E–04), and PYY (P =3.0E–02); by
contrast, environmental covariance (or shared environmental determination, ρE) was not
significant for these same traits.
Polymorphism discovery across NPY2R
Located on chromosome 4q31, NPY2R spans two exons (one coding) with one intervening
sequence (intron). We resequenced approximately 1800 bp of proximal promoter, each of
exon-1 and exon-2 [down to the first polyadenylation site (bold): 5′-
TACTAAATAAAACAAT-3′], and adjacent intron/exon borders (Fig. 2) in 2n =160
chromosomes derived from four biogeographic ancestry groups (Table 1). We identified 21
variants (18 SNPs, 3Ins/Del) in these individuals. Of these variants, 10 are common [minor
allele frequency (MAF) >5%], including two in the open reading frame within coding
exon-2 (both synonymous), T +5895C (Ile195Ile) and T +6242C (Ile312Ile), whereas the
rest are located in the proximal promoter.
Biogeographic ancestry and NPY2R linkage disequilibrium
NPY2R common allele frequencies did not differ across the four biogeographic ancestry
groups (Table 1). To visualize patterns of marker-on-marker association, pair-wise linkage
disequilibrium correlations among the eight common (MAF >5%) SNPs were quantified by
the confidence interval method across the NPY2R locus. In each biogeographic ancestry
group, two blocks of linkage disequilibrium were maintained, with one in the promoter
region (Fig. 3a).
Neuropeptide Y2 receptor haplotype effects on traits
We ‘tagged’ the human NPY2R gene with three SNPs spanning the locus (Fig. 3b):
haplotype GTT (found on 11.1% of chromosomes) was associated significantly with both
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BMI (P =3.75E–04) and PYY secretion (P =4.01E–06), and the principal effect accrued to
GTT homozygotes (with two copies of that haplotype per diploid genome); the GTT effect
size (or slope) was positive for BMI (1.93 ± 0.48 kg/m2 per copy), although negative for
PYY (−26.3 ±5.65 pg/ml per copy). Perhaps these pleiotropic effects of haplotype GTT
involve increased response to PYY, with consequent fall in this anorexigenic hormone and
ultimately an increase in BMI.
Endogenous NPY2R mRNA expression in a disease model in rodents: spontaneously
hypertensive rat/Wistar–Kyoto rat
NPY2R mRNA expression was increased significantly in two key neuroendocrine tissues of
the SHR (Fig. 4a): both the adrenal gland (by ~2.6-fold, P =0.002) and the brainstem (by
~1.5-fold, P =0.027).
Genetic variation in the proximal human NPY2R promoter: consensus motifs
Core promoter: nonpolymorphic motifs—Motifs identified did not include a
consensus TATA box near the transcriptional start site; the closest partial TATA (i.e., T/A-
rich) match on the (+) strand was 5′-(−113 bp)-AAAcTT-(−108 bp)-3′, whereas the nearest
potential CAAT box was on the (−) strand at 5′ (−420 bp)-CCAAT (−424 bp)-3′. There was
no proximal cAMP response element. The 13 G/C-rich (consecutive G/C ≥6 bp) regions
were noted in the proximal promoter, as were 4 E-boxes (CANNTG). One of the G/C-rich
domains constituted a consensus match for a B recognition element [27], on the very
proximal (+) strand at 5′-(−49 bp) GGGCGCC (−43 bp)-3′. The closest potential initiator
(Inr) elements [28] (consensus 5′-YYA+1NWYY-3′) were located at 5′-(−244
bp)CCAGTCC(−238 bp)-3′ (+ strand) and 5′-(+151 bp)TTACACT(+145 bp)-3′ (− strand).
None of these core elements were polymorphic across 2n =160 human chromosomes.
Polymorphisms—We identified 16 polymorphisms in the promoter (Table 1), eight of
which were common (MAF >5%). Of note, the very proximal ‘core’ promoter (−186/+85
bp) was devoid of common variation. At promoter variants G-1606A, C-599T, and A-224G,
we identified motifs likely to be disrupted by the sequence change (see below).
NPY2R promoter haplotypes affect gene expression—Constructed from three
common SNPs (G-1606A, C-599T and A-224G) that were predicted to be functional (see
below), eight haplotypes were created by site-directed mutagenesis from the most common
promoter haplotype (alleles: G-1606, C-599 and A-224; 55.4% of chromosomes in our
sample). NPY2R promoter/luciferase reporters with various haplotypes had significantly
different expression activities (one-way ANOVA: P =1.12E–23; Fig. 5a). We used two-way
ANOVA to probe individual SNP effects on gene expression: each individual SNP, as well
as their binary and ternary interactions, displayed significant influences on reporter
expression (P =5.00E–06; Fig. 5b).
Neuropeptide Y2 receptor G-1606A polymorphism: role of an IRF1 activator-binding site
Sequence conservation/alignment—G-1606A is located in a region highly conserved
across sequenced primates (Fig. 4a), with the G allele ancestral in the human lineage, as
judged by the chimp sequence (Fig. 6a). In this conserved local region, there is a partial
consensus match for an IRF1 site (VAAARYGAAASY; −1606 in bold) with an improved
match for the A allele (10/12 bp match) over the G allele (9/12 bp match) (Fig. 4a).
Exogenous IRF1 transcription factor: increased NPY2R promoter-driven
reporter expression, A>G allele—During NPY2R promoter/luciferase reporter
transfection/expression into chromaffin cells (cotransfection with empty vector pcDNA 3.1;
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Fig. 6b), the A allele displayed greater expression than the G allele (A>G). Cotransfection/
expression of the IRF1 transcription factor increased reporter expression and amplified the
difference in expression between the two alleles (Fig. 4b, P =0.001).
Exogenous IRF1 siRNA: decreased NPY2R promoter-driven reporter
expression, A>G allele—During NPY2R promoter/luciferase reporter cotransfection
with negative control siRNA into chromaffin cells (Fig. 6c), the A allele once again
displayed greater expression than the G allele (A>G). Cotransfection of IRF1 siRNA
decreased reporter expression and attenuated the difference of expression between the two
alleles (Fig. 6C, P =8.72E–06).
Neuropeptide Y2 receptor C-599T polymorphism: role of an activator FOXI1 binding site
Sequence conservation/alignment—C-599T is located in a region highly conserved
across sequenced primates (Fig. 7a), with the T allele ancestral in the human lineage, as
judged by the chimp sequence (Fig. 7a). In this conserved local region, there is a total
consensus match for a FOXI1 site (TRTTTRKWD; −599 in bold) with an improved match
for the T allele (9/9 bp match) over the C allele (8/9 bp match) (Fig. 7a).
Exogenous FOXI1 transcription factor: increase in NPY2R promoter-driven
reporter expression, T>C allele—During NPY2R promoter/luciferase reporter
transfection into chromaffin cells (cotransfection with empty vector pcDNA 3.1; Fig. 7b),
the T allele displayed greater expression than the C allele (T>C). Cotransfection/expression
of FOXI1 transcription factor increased reporter expression and amplified the difference of
expression between the two alleles (Fig. 7b, P =5.57E–06).
Exogenous FOXI1 siRNA: decrease in NPY2R promoter-driven reporter
expression, T>C allele—During NPY2R promoter/luciferase reporter, cotransfection
with negative control siRNA into chromaffin cells (Fig. 7c), the T allele displayed greater
expression than the C allele (T>C). Cotransfection of FOXI1 siRNA decreased reporter
expression and attenuated the difference of expression between two alleles (Fig. 7c, P
=0.010).
Neuropeptide Y2 receptor A-224G polymorphism: role of a SNAI1 repressor binding site
Sequence conservation/alignment—A-224G is located in a region highly conserved
across sequenced primates (Fig. 8a), with the A allele ancestral in the human lineage, as
judged by the chimp sequence (Fig. 8a). In this conserved local region, there is a partial
consensus match for an SNAI1 site (CAGGTG; −224 in bold) with an improved match for
the A allele (5/6 bp match) over the G allele (4/6 bp match) (Fig. 8a).
Exogenous SNAI1 transcription factor: decrease in NPY2R promoter-driven
reporter expression, A>G allele—During NPY2R promoter/luciferase reporter
transfection into chromaffin cells (cotransfection with empty vector pcDNA 3.1; Fig. 8b),
the G allele displayed greater expression than the A allele (G>A). Cotransfection of the
SNAI1 transcription factor decreased reporter expression and amplified the difference of
expression between the two alleles (Fig. 8b, P =0.034).
Exogenous SNAI1 siRNA: increase in NPY2R promoter-driven reporter
expression, A>G allele—During NPY2R promoter/luciferase reporter cotransfection
with negative control siRNA into chromaffin cells (Fig. 8c), the G allele displayed greater
expression than the A allele (G>A). Cotransfection of SNAI1 siRNA increased reporter
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expression and attenuated the difference of expression between two alleles (Fig. 8c, P
=0.019).
Endogenous mRNA expression in neuroendocrine cells: NPY2R and
transcription factors whose binding is disrupted by NPY2R promoter common
genetic variation (IRF1, FOXI1, SNAI1)—We used PC12 (rat pheochromocytoma) cells
as an experimental system to test the effects of potentially allele-specific transcription
factors, but are the receptor and these transcription factors endogenously expressed in this
model system (Fig. 4b)? NPY2R itself, as well as the transcription factors IRF1 and SNAI1,




NPY2R represents a central control point for the PYY/NPY regulatory pathway. In this
study, we explored whether and how common genetic variations in the NPY2R promoter
affect gene expression. We present evidence from several approaches (genomic,
bioinformatic, transfection, trans-activation, and siRNA inhibition) in which we found that
promoter variants G-1606A, C-599T, and A-224G conferred functional changes onto
NPY2R expression, and that particular transcription factors were implicated. We, thus,
present evidence of previously unexpected cis-variation in the regulation of NPY2R
expression.
Cardiometabolic traits and NPY2R genetic variation
We found that multiple cardiometabolic traits are highly heritable, and also display shared
genetic determination (Fig. 1). Associations between NPY2R SNPs and obesity are widely
investigated in multiple populations, with substantial agreement that significant marker-on-
trait effects occur [29]. We too could replicate such effects, in that a haplotype across the
NPY2R locus influenced both BMI and PYY (Fig. 3b). Thus, in this report we describe a
potential genetic contributor to dysregulation of body mass: genetic variation at the NPY2R
locus (Figs 2 and 3).
Neuropeptide Y2 receptor promoter variants G-1606A, C-599T, and A-224G
We focused on three promoter polymorphisms that are not only common (high MAF) but
also predicted to influence transcription factor binding, by bioinformatic analyses. On the
basis of this strategy, the G-1606A, C-599T, and A-224G were advanced to further
investigation. Frequencies of their promoter haplotypes are shown in Fig. 5.
Of note for the physiological significance of these results, we detected abundant transcripts
in neuroendocrine PC12 cells (Fig. 4b) for NPY2R itself, IRF1, and SNAI1. In addition,
query of the NCBI GEO database (http://www.ncbi.nlm.nih.gov/geo/) indicates that
transcripts for NPY2R, IRF1 (binding G-1606A), FOXI1 (binding C-599T), and SNAI1
(binding A-224G) are expressed endogenously in PC12 chromaffin cells, by inspection of
the following GEO transcript datasets: GDS3436 [30], GDS1038–1039 [31], and GDS2555
[32].
Results in context with the literature
Common genetic variation in the NPY2R promoter [2,3,6] has been associated with obesity
or BMI traits in studies of over 10 000 individuals (on-line Table 1, http://links.lww.com/
HJH/A209); in one case [6], the effect size (as Cramer’s phi) suggested that NPY2R
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promoter genetic variation might account for up to approximately 9.3% of trait variance in
the population. Among the three promoter variants evaluated in depth in our studies, C-599T
(rs6857715) was implicated in one of these association studies: C-599T was associated with
both adult and childhood obesity in a French sample [6], and this variant also had an effect
on high-density lipoprotein cholesterol [8]; C-599T was a component of functional promoter
haplo-types on gene expression (Figs 5 and 7) as well as the BMI/PYY-associated GTT
haplotype in our population (Fig. 3b).
Furthermore, each of the three transcription factors (Figs 6–8) whose binding is altered by
NPY2R promoter variants is already implicated in cardiometabolic function. A meta-
analysis of genome-wide association studies revealed the influence of IRF1 on circulating
C-reactive protein level, which is strongly associated with cardiovascular disease [33]. IRF1
also plays a key role in development of insulitis and diabetes in a mouse model [34]. FOXI1
may be necessary for expression of at least four subunits and proper assembly of the
vacuolar H+-ATPase complex [35], whose activity has an impact on hypertension [36].
SNAI1 transcriptionally controls cardiovascular progenitor cell formation through epicardial
epithelial-mesenchymal transition [37], and such function is regulated by glucose
metabolism [38].
Limitations of this study
A number of issues remain unexplored by our studies. For effects in very large sample sizes
(>10 000 participants; on-line Table 1, http://links.lww.com/HJH/A209), we rely on the
findings of other groups [2,3,6] that NPY2R promoter polymorphism influences obesity,
especially for C-599T [6], although we did find evidence for such effects in our own
population (Fig. 3b). Second, the cis-interactions/trans-interactions that we observed in
transfected cells (Figs 6–8) are novel, and thus not yet established in vivo, although we did
find evidence of differential expression of NPY2R in neuroendocrine tissues of the SHR
(Fig. 4a), as well as endogenous expression of the pertinent transcripts in neuroendocrine
cells (Fig. 4b).
Conclusions and perspectives
We conclude that cardiometabolic traits are highly heritable, that NPY genetic variation
influences such traits (including BMI and PYY), and that within the NPY2R promoter,
common polymorphisms are associated with alterations in transcriptional efficiency. The
functional effects of polymorphism seem to arise from differential actions of specific
transcription factors at the NPY2R promoter: IRF1 functioning as an activator disrupted by
G-1606A bi-allelic variation, FOXI1 acting as an activator disrupted by C-599T, and SNAI1
acting as a repressor disrupted by A-224G. The results raise the potential for novel
alterations in cis-interactions for control of PYY responses, thus, augmenting our
understanding of molecular events underlying interindividual variation in energy balance,
and the genetic predisposition toward obesity, a potent risk factor for cardiovascular disease.
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Heredity, pleiotropy, and human cardiometabolic traits. (a) Heritability (h2): twin pair
variance components. h2 is the fraction of trait variance accounted for by genetic variance
(i.e., h2 =VG/VP). h2 (±SEM, with significance for h2) is displayed for BMI, SBP, DBP, and
circulating plasma peptide YY (PYY) concentration. (b) Pleiotropy: shared genetic
determination, or genetic covariance (ρG) for BMI with other cardiometabolic traits.
Genetic (ρG) and environmental (ρE) covariance estimates, from the twin pair studies above,
are illustrated graphically, as mean ± SEM for each covariance, with P-value for its
significance.
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NPY2R resequencing strategy and identified variants. Sequences conserved between mouse
and human NPY2R were visualized with VISTA (http://genome.lbl.gov/vista/index.shtml).
Locations of common (minor allele frequency ≥5%) single nucleotide polymorphisms
(SNPs) are indicated. Positions are numbered upstream (−) or downstream (+) of the CAP
(transcription initiation) site. Solid blocks, open reading frame (ORF); hatched blocks,
UTRs. Bi-directional horizontal arrows, resequencing amplicons, with sequencing
direction(s) indicated by arrowheads.
Wei et al. Page 15














Haplotype analyses at the NPY2R locus. (a) Linkage disequilibrium (LD) blocks across
NPY2R in several biogeographic ancestry groups, derived by confidence intervals in
Haploview. Numerical values shown in diamonds are r2 × 100. r2 color scheme: r2 =0,
white; 0<r2<1, shades of grey; r2 =1, black. Common single nucleotide polymorphisms
(SNPs): MAF ≥5%. Rectangles, exons; Diagonal shading, noncoding (UTR); Solid shading,
coding (open reading frame). (b) Polymorphism at NPY2R influences human
cardiometabolic traits: haplotype effects across the locus, ‘tagged’ by three SNPs (see Fig. 1
rs6851222 (Promoter G-1606A), rs6857715 (Promoter C-599T), and rs1047214 (Exon-2T/C
Ile195Ile), chosen to span the NPY2R locus. Each SNP was in Hardy–Weinberg equilibrium
(all P >0.05). Both BMI and circulating peptide YY (PYY) were significantly influenced by
the GTT haplotype, and the effects displayed evidence of joint determination (genetic
pleiotropy).
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Transcript (mRNA) expression for the NPY2R system, in tissues in vivo as well as in
cultured neuroendocrine cells. Results were obtained by RT-PCR, using the ΔΔCt method
for normalization and condition comparisons. (a) Experimental (genetic) hypertension,
differential expression of NPY2R in SHR and WKY neuroendocrine tissues (adrenal gland
and brainstem). WKY, Wistar–Kyoto rat as a normotensive control; SHR, spontaneously
hypertensive rat as a polygenic hypertension model. N =9 in each group. (b) Cultured
neuroendocrine cells: presence of transcripts for NPY2R as well as transcription factors
IRF1, FOXI1, and SNAI1 in rat PC12 cells. The negative control (human elastin gene) was
measured to define the threshold of expression. Genes with significantly higher expression
than negative control are marked by an asterisk (*). N =4 samples in each group.
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NPY2R haplotypes influence luciferase reporter expression. (a) Eight haplotypes
constructed by the combination of three single nucleotide polymorphisms (SNPs) have
significantly different effects on expression of the reporter (one-way ANOVA: P =1.12E–
23). The minor allele for each SNP is shown in bold. Frequency of each haplotype in our
resequencing sample is shown at the bottom. Results for n =8 groups are shown. (b) Single
SNPs and their binary and ternary interactions were examined using two-way ANOVA, and
found to all have significant effects on reporter expression.
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NPY2R promoter variant G-1606A: role of IRF1. (a) Consensus motif match for IRF1
(interferon regulatory factor-1) at G-1606A across primate species. (b) Exogenous IRF1
cDNA enhanced reporter expression driven by NPY2R promoter, significantly more on the
−1606A allele. (c) Exogenous IRF1 siRNA impaired the activator function of IRF1 on
reporter expression driven by NPY2R promoter, significantly more on the −1606A allele. N
=6 in each group.
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NPY2R promoter variant C-599T: role of FOXI1. (a) Consensus motif match for FOXI1
(Forkhead Box I-1) at C-599T across primate species. (b) Exogenous FOXI1 cDNA
enhanced reporter expression driven by NPY2R promoter, significantly more on the −599T
allele. (c) Exogenous FOXI1 siRNA impaired the activator function of FOXI1 on reporter
expression driven by NPY2R promoter, significantly more on the −599T allele. N =6 in each
group.
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NPY2R promoter variant A-224G: role of SNAI1. (a) Consensus motif match for SNAI1
(Snail homolog 1) at A-224G across primate species. (b) Exogenous SNAI1 cDNA inhibited
reporter expression driven by NPY2R promoter, significantly more on the A-224 allele. (c)
Exogenous SNAI1 siRNA impaired the repressor function of IRF1 on reporter expression
driven by NPY2R promoter, significantly more on the A-224 allele. N =6 in each group.
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